11/9/2020

speaker
Kathy
Operator

Ladies and gentlemen, thank you for standing by. Welcome to Infinity Pharmaceuticals conference call to discuss the company's operations and financial results for the third quarter 2020. My name is Kathy, and I'll be your operator for today's call. At this time, all participants are in a listen-only mode. There will be a question and answer session to follow. Please be advised that this call is being recorded at Infinity's request. Now I would like to introduce your host for today's call, Jane Kaufman. Please go ahead.

speaker
Jane Kaufman
Host

Thank you, Kathy, and good afternoon, everyone. Welcome to today's call to discuss our recent business progress and review our third quarter 2020 financial results. On the call with me today are Adeline Perkins, Chief Executive Officer, Larry Block, President, and Brian Schwartz, Consulting Chief Physician. We will open up the call for Q&A following our remarks. The press release issued this afternoon details our results and is available on our website at infi.com. Please note that during this call, we may make forward-looking statements about our future expectations and plans, including clinical development objectives, the therapeutic potential of our product candidates, our strategic plans and strategies, and financial projections. Our actual results may differ materially from what we project today. due to a number of important factors, including the considerations described in the risk factor section of our quarterly report on Form 10-Q for the third quarter of 2020, and in other filings we make with the SEC. These forward-looking statements represent our views only as of today, and we caution you that we may not update them in the future, whether as a result of new information, future events, or otherwise. Now, I would like to turn the call over to Adeline.

speaker
Adeline Perkins
Chief Executive Officer

Thanks, Jane, and thank you to everyone for joining us today. We are reaching an exciting inflection point in InfiniDate, having progressed the development of Eganilisib toward data readouts across our clinical program in diverse treatment settings and indications, strategically designed to evaluate the potential of Eganilisib to improve outcomes for cancer patients. Over the past two years, we have focused on the execution of our Phase II clinical trials leveraging the strong scientific foundation of PI3 kinase gamma inhibition with aganalysib, and are now positioned to deliver important clinical and translational data in the coming months. On today's call, our Consultant Chief Physician, Dr. Brian Schwartz, will provide more detailed clinical updates. But before that, I'd like to review some highlights from the past quarter. Starting off with MERIA-275. our randomized control phase two study in collaboration with BMS, in which we are evaluating aganalysib in combination with Opivo in patients with advanced urothelial cancer. We previously announced that we reduced the dose of aganalysib from 40 milligrams to 30 milligrams daily to address the reversible liver enzyme elevations, which were reported at the first scheduled IDMC meeting last spring. We've continued treatment of patients still on study at 30 milligrams and have continued monitoring the safety of the 49 patients enrolled in the study to date. And we recently reviewed updated data from these patients with the IDMC. We're pleased that the IDMC concluded that the risk-benefit ratio of aganalysib and Opdivo in this patient population warrants ongoing evaluation. We will continue to follow the patients still on study through year end and evaluate data on maturing time-to-event measures, including progression-free survival and overall survival, to determine the best path forward for aganalysib plus Opdivo in second-line bladder cancer. I will now move to Mario 3, our Phase 2 study in collaboration with Roche Genentech, in which we are evaluating the combination of aganalysib with ticentric and abracadabra as a frontline treatment in patients with triple-negative breast cancer, or TNBC, and in combination with Dicentric and Avastin as a frontline treatment for patients with renal cell cancer, or RCC. Last quarter, we shared that we were on track to present data from the TNBC cohort of MERIO-3 and have been accepted to present these results at the San Antonio Breast Cancer Symposium, or SABC, next month. We were also pleased to have received fast-track designation for ganylysin in combination with a checkpoint inhibitor and chemotherapy for first-line treatment of patients with advanced TNBC. This week, at CISSE, our investigators are presenting updated data from the melanoma and squamous cell cancer of the head and neck cohorts of MERIA-1, our Phase 1, 1B study in collaboration with Krister Meyers Squibb, evaluating aganalysib in combination with Updivo in patients with advanced solid tumors. These data support the tolerability and activity of this combination and provide additional translational data supporting both the on-mechanism immune modulation of aganalysib and our clinical strategy to move aganalysib to earlier lines of treatment. And finally, in addition to these INFINITY-sponsored trials, our collaborator, Arcus Biosciences, will also be presenting data at SABC from their Phase 1b study, evaluating aganalysib in a novel checkpoint inhibitor-free regimen that includes the Trumadant, their dual receptor antagonist, the identity antagonist, also known as AB928, and Doxil in patients with relapsed refractory triple negative breast cancer, adding to our aganalysis data set in TNBC. We are pleased with our progress in the clinic, which enables us to share data over the coming months that reveal the potential of aganalysis. We're grateful for the commitment and dedication of our employees, collaborators, and partners who have enabled this progress. With that overview, I will now transition the call over to Brian to provide more detail on our trials and upcoming data presentation.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-